Answers are grounded in this paper and cite their sources.
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles: Editorial1 Nov 2003Editorial: Bladder Cancer. How Can We Make a Difference? Mark S. Soloway Mark S. SolowayMark S. Soloway More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000092149.02524.65AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Editorial: Bladder Cancer. How Can We Make a Difference?." The Journal of Urology, 170(5), pp. 1781–1782 References 1 : Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol2002; 20: 3061. Google Scholar 2 : Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol1999; 10: 1301. Google Scholar 3 : De novo muscle invasive bladder cancer: is there a change in trend?. J Urol2001; 165: 47. Link, Google Scholar Department of Urology, University of Miami School of Medicine, Miami, Florida© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byDANILTCHENKO D, RIEDL C, SACHS M, KOENIG F, DAHA K, PFLUEGER H, LOENING S and SCHNORR D (2018) LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDYJournal of Urology, VOL. 174, NO. 6, (2129-2133), Online publication date: 1-Dec-2005. Volume 170Issue 5November 2003Page: 1781-1782 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.MetricsAuthor Information Mark S. Soloway More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Mark S. Soloway (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: